The evolution of progesterone receptor ligands

書誌事項

公開日
2006-09-29
権利情報
  • http://onlinelibrary.wiley.com/termsAndConditions#vor
DOI
  • 10.1002/med.20083
公開者
Wiley

この論文をさがす

説明

<jats:title>Abstract</jats:title><jats:p>Progesterone is one of the first nuclear receptor hormones to be described functionally and subsequently approached as a drug target. Because progesterone (<jats:bold>1</jats:bold>) affects both menstruation and gestation <jats:italic>via</jats:italic> the progesterone receptor (PR), research aimed at modulating its activity is usually surrounded by controversy. However, ligands for PR were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug‐like steroids that mimic the gestational properties of progesterone; (2) drug‐like steroids with different properties from progesterone and expanded therapeutic applications; and (3) non‐steroidal PR ligands with improved selectivity and modulator properties and further expanded therapeutic applications. Although the latter have yet to see widespread clinical applications, their development is founded on a half century of research, and they represent the future for this drug target. © 2006 Wiley Periodicals, Inc. Med Res Rev, 27, No. 3, 374–400, 2007</jats:p>

収録刊行物

被引用文献 (5)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ